Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.64 |
| ▸ | RARA | P10276 | 3/20 | 0.42 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | RARG | P13631 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774407 | 0.93 | S1PR1 (0.73) | S1PR1S1PR3RARARARBRARG | |
| SCHEMBL2774458 | 0.89 | S1PR1 (0.58) | S1PR1S1PR3RARARARBRARG | |
| SCHEMBL411050 | 0.89 | S1PR1 (0.81) | S1PR1S1PR3NPC1RAB9A | |
| SCHEMBL2772296 | 0.89 | S1PR1 (0.67) | S1PR1S1PR3RARARARBRARG | |
| SCHEMBL2773628 | 0.88 | S1PR1 (0.66) | S1PR1S1PR3RARARARBRARG | |
| SCHEMBL2772309 | 0.87 | S1PR1 (0.70) | S1PR1S1PR3RARARARBRARG | |
| SCHEMBL2771975 | 0.87 | S1PR1 (0.70) | S1PR1S1PR3RARARARBRARG | |
| SCHEMBL2774348 | 0.86 | S1PR1 (0.63) | S1PR1S1PR3RARARARBRARG | |
| SCHEMBL2772469 | 0.86 | S1PR1 (0.69) | S1PR1S1PR3NPC1RAB9AMAPT | |
| SCHEMBL2773937 | 0.86 | S1PR1 (0.61) | S1PR1S1PR3RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2193125-A2 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | S1PR1 483/4885S1PR3 335/4885RARA 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.